Latest Anthracyclines Stories
A Follow-On Combination Trial in First-Line Ovarian Cancer in the Neo-Adjuvant Setting Has Been Accepted by FDA LAWRENCEVILLE, N.J., Feb.
LAGUNA HILLS, Calif., Feb.
BIRMINGHAM, Ala., Jan.
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
Company does not expect estimated timelines to materially change LOS ANGELES, Jan.
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.
QUÉBEC CITY, Dec. 29, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
Company Continues to Expect Clinical Trial Timelines to Remain Materially Unchanged and Expeditiously Resolved LOS ANGELES, Dec.
Company expects Induction Response Rate data in Second Quarter of 2015 EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc.
All amounts are in U.S. dollars QUÉBEC CITY, Dec. 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
- A political dynamiter.